Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization

PURPOSE: Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA class II–IV) and reduced ejection fraction. This study w...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur J Clin Pharmacol
Main Authors: Langenickel, Thomas H., Jordaan, Pierre, Petruck, Jesika, Kode, Kiran, Pal, Parasar, Vaidya, Soniya, Chandra, Priya, Rajman, Iris
Formato: Artigo
Idioma:Inglês
Publicado: Springer Berlin Heidelberg 2016
Assuntos:
Clinical Trial
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4942489/
https://ncbi.nlm.nih.gov/pubmed/27083930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00228-016-2062-9
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares